GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enorama Pharma AB (OSTO:ERMA) » Definitions » Debt-to-Equity

Enorama Pharma AB (OSTO:ERMA) Debt-to-Equity : 0.02 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Enorama Pharma AB Debt-to-Equity?

Enorama Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.40 Mil. Enorama Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Enorama Pharma AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr19.71 Mil. Enorama Pharma AB's debt to equity for the quarter that ended in Mar. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Enorama Pharma AB's Debt-to-Equity or its related term are showing as below:

OSTO:ERMA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02   Med: 0.18   Max: 3.21
Current: 0.02

During the past 10 years, the highest Debt-to-Equity Ratio of Enorama Pharma AB was 3.21. The lowest was 0.02. And the median was 0.18.

OSTO:ERMA's Debt-to-Equity is ranked better than
92.69% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs OSTO:ERMA: 0.02

Enorama Pharma AB Debt-to-Equity Historical Data

The historical data trend for Enorama Pharma AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enorama Pharma AB Debt-to-Equity Chart

Enorama Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.21 0.18 0.06 0.02

Enorama Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.05 0.02 0.02 0.02

Competitive Comparison of Enorama Pharma AB's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enorama Pharma AB's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's Debt-to-Equity falls into.



Enorama Pharma AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Enorama Pharma AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Enorama Pharma AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enorama Pharma AB  (OSTO:ERMA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Enorama Pharma AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Enorama Pharma AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Enorama Pharma AB (OSTO:ERMA) Business Description

Traded in Other Exchanges
N/A
Address
Sodergatan 3, Malmo, SWE, SE-211 34
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.

Enorama Pharma AB (OSTO:ERMA) Headlines

No Headlines